Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta‐Analysis of Randomized Controlled Trials

摘要: Objectives The aim of this meta-analysis was to evaluate the efficacy and safety duloxetine for management osteoarthritis knee (OAK) pain. Methods A systematic literature search articles OAK using were performed in PubMed, EBSCO, EMBASE, ScienceDirect, MEDLINE, [ClinicalTrials.gov][1], Google Scholar, Cochrane Central Register Controlled Trials from available date inception until latest issue (October 2013). Potentially relevant randomized controlled trials (RCTs) regarding comparison with placebo managing pain included. Also, studies specific data reductions response rate, Patient Global Impression Improvement (PGI-I), functional improvement, Western Ontario McMaster Osteoarthritis Index (WOMAC), adverse events (AEs), treatment-emergent AEs (TEAEs), mortality included analyzed, those confounding conditions excluded. Studies assessed quality Jadad five-point score RCTs. Finally, a all RCTs eligible inclusion criteria Review Manager 5.1 software. Results. Three that enrolled 1,011 patients our meta-analysis. There statistically significant differences between taking regard intensity (992 patients, mean difference [MD] = −0.88, 95% confidence interval [CI] −1.11–−0.65, P 30% rate; 989 risk ratio [RR] 1.49, CI 1.31–1.70, =50% RR 1.69, 1.27–2.25, 0.0004). Statistically PGI-I (976 MD −0.47, −0.63 −0.30, < 0.0001) WOMAC—physical function subscale (977 −4.25, −5.82 −2.68, observed. Similarly, more AEs, TEAEs, discontinuations any reason associated use than (1,011 2.15, 1.48–3.11, 0.0001; 1.32, 1.16–1.49, 1.43, 1.14–1.78, 0.002, respectively). However, serious not significantly different. Moreover, no deaths occurred during these three studies. Conclusion. This analysis suggests (60/120 mg quaque die (QD)), compared control, resulted greater reduction pain, improved patient-rated impression acceptable effects treatment after approximately 10 −13 weeks treatment. [1]: http://ClinicalTrials.gov